Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Validation of tissue microarray technology in breast carcinoma.

R L Camp1, L A Charette, D L Rimm

  • 1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

Laboratory Investigation; a Journal of Technical Methods and Pathology
|January 5, 2001
PubMed
Summary

Tissue microarray technology enables large studies using archival tissues. Analyzing just two tissue disks accurately represents protein expression in invasive breast carcinoma, similar to whole sections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Corrigendum to "Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma" [Oral Oncol. 86 (2018) 278-287].

Oral oncology·2019
Same author

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Immunological differences between primary and metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Nature communications·2018

Area of Science:

  • Oncology
  • Pathology
  • Biotechnology

Background:

  • Tissue microarray (TMA) technology allows large-scale retrospective studies using archival formalin-fixed, paraffin-embedded tissues.
  • A key limitation of TMAs is the reduced tissue sample size (0.6 mm diameter disks), raising concerns about representativeness of protein expression compared to whole tissue sections.

Purpose of the Study:

  • To determine the optimal number of tissue microarray disks required for accurate representation of protein expression in invasive breast carcinoma.
  • To assess the antigenicity of proteins in archival tissues for long-term studies.

Main Methods:

  • Compared protein expression (estrogen receptor, progesterone receptor, Her2/neu oncogene) in 2 to 10 TMA disks versus whole tissue sections from 38 invasive breast carcinoma cases.
  • Constructed a breast cancer TMA using cases from 1932 to the present to evaluate long-term antigenicity.

Related Experiment Videos

Main Results:

  • Analysis of two TMA disks provided results comparable to whole tissue sections in over 95% of cases for the evaluated antigens.
  • Proteins retained antigenicity in archival tissues for over 60 years, validating the use of these tissues in TMAs.

Conclusions:

  • Tissue microarray technology, with a minimum of two disks per case (2-fold redundancy), is a validated, accurate method for analyzing protein expression in large archival cohorts.
  • TMAs are suitable for large-scale retrospective studies utilizing the wealth of information stored in archival tissues.